Publication Date:
2018-08-02
Description:
Key Points GC-sparing treatment alternatives are a critical need for patients with HESs. The orally bioactive drug dexpramipexole demonstrated clinical efficacy with an excellent safety profile in a subset of patients with HESs.
Print ISSN:
0006-4971
Electronic ISSN:
1528-0020
Topics:
Biology
,
Medicine
Permalink